LifeVantage Corp

LifeVantage maintains a strong liquidity position with $20.2 million in cash and equivalents, representing 55.4% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 25.7%, and its current ratio of 1.87 indicates a solid ability to meet short-term obligations. The absence of long-term debt and a debt-to-equity ratio of 0.0 further reinforce its conservative capital structure. Profitability metrics show a return on equity (ROE) of 28.3% and a return on assets (ROA) of 13.6%, both exceeding the median for the Pharmaceuticals industry. The company's gross margin of 80.4% is robust, but its operating margin of 5.3% is below the industry median, suggesting potential inefficiencies in cost management. Geographically, LifeVantage's revenue is concentrated in the United States, with over 70% of total revenue derived from domestic operations. The company's business is heavily reliant on its direct sales model, which is sensitive to distributor retention and market saturation. Outlook data indicates a projected 12.5% revenue growth in the current fiscal year and 15.0% in the next, driven by new product launches and international expansion. Historical revenue growth has averaged 8.2% annually over the past five years, suggesting a moderate but consistent growth trajectory. Risk assessment reveals a low liquidity risk and a low dilution potential, with no immediate filing-based flags detected. The company's conservative capital structure and strong cash position mitigate financial risk. However, the reliance on a direct sales model and the competitive nature of the health and wellness market pose operational risks. Recent events include the filing of a 10-K for the fiscal year ending April 2026, which disclosed continued investment in product innovation and digital marketing. No significant regulatory or legal issues were reported in the latest filings.